Michael Dubina

Prof. Dr. Michael Dubina

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2017 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
STStanislav Terekhov
Stanislav Terekhov
ISIvan V. Smirnov
Ivan V. Smirnov
ASAnastasiya V. Stepanova
Anastasiya V. Stepanova
TBTatyana V. Bobik
Tatyana V. Bobik
YMYuliana Mokrushina
Yuliana Mokrushina
SASidney Altman
Sidney Altman
Ultrahigh-throughput screening (uHTS) techniques can identify unique functionality from millions of variants. To mimic the natural selection mechanisms that occur by compartmentalization in vivo, we developed a technique based on single-cell encapsulation in droplets of a monodisperse microfluidic double water-in-oil-in-water emulsion (MDE). Biocompatible MDE enables in-droplet cultivation of different living species. The combination of droplet-generating machinery with FACS followed by next-generation sequencing and liquid chromatography-mass spectrometry analysis of the secretomes of encapsulated organisms yielded detailed genotype/phenotype descriptions. This platform was probed with uHTS for biocatalysts anchored to yeast with enrichment close to the theoretically calculated limit and cell-to-cell interactions. MDE–FACS allowed the identification of human butyrylcholinesterase mutants that undergo self-reactivation after inhibition by the organophosphorus agent paraoxon. The versatility of the platform allowed the identification of bacteria, including slow-growing oral microbiota species that suppress the growth of a common pathogen, Staphylococcus aureus, and predicted which genera were associated with inhibitory activity. Significance Biocompatible microfluidic double water-in-oil-in-water emulsion (MDE) enables in-droplet cultivation of different living species. The combination of droplet-generating machinery with FACS followed by next-generation sequencing and liquid chromatography-mass spectrometry analysis of the secretomes of encapsulated organisms yielded detailed genotype/phenotype descriptions. The MDE–FACS platform we developed enabled highly sensitive single-cell selection of predesigned activity and exploration of pairwise interactions between target and effector cells without interference from other microbiota species.

29 May 2017 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TATin Aung
Tin Aung
MOMineo Ozaki
Mineo Ozaki
MLMei Chin Lee
Mei Chin Lee
USUrsula Schlötzer-Schrehardt
Ursula Schlötzer-Schrehardt
GTGudmar Thorleifsson
Gudmar Thorleifsson
CKChiea Chuen Khor
Chiea Chuen Khor

23 February 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TATin Aung
Tin Aung
MOMineo Ozaki
Mineo Ozaki
TMTakanori Mizoguchi
Takanori Mizoguchi
RAR Rand Allingham
R Rand Allingham
ZLZheng Li
Zheng Li
CKChiea-Chuen Khor
Chiea-Chuen Khor

9 October 2012 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
ABAlexey A. Belogurov
Alexey A. Belogurov
ASAlexey V. Stepanov
Alexey V. Stepanov
ISIvan V. Smirnov
Ivan V. Smirnov
DMDobroslav Melamed
Dobroslav Melamed
ABAndrew Bacon
Andrew Bacon
AGAlexander Gabibov
Alexander Gabibov
Multiple sclerosis (MS) is a severe inflammatory and neurodegenerative disease with an autoimmune background. Despite the variety of therapeutics available against MS, the development of novel approaches to its treatment is of high importance in modern pharmaceutics. In this study, experimental autoimmune encephalomyelitis (EAE) in Dark Agouti rats has been treated with immunodominant peptides of the myelin basic protein (MBP) encapsulated in mannosylated small unilamellar vesicles. The results show that liposome‐encapsulated MBP 46–62 is the most effective in reducing maximal disease score during the first attack, while MBP 124–139 and MBP 147–170 can completely prevent the development of the exacerbation stage. Both mannosylation of liposomes and encapsulation of peptides are critical for the therapeutic effect, since neither naked peptides nor nonmannosylated liposomes, loaded or empty, have proved effective. The liposome‐mediated synergistic effect of the mixture of 3 MBP peptides significantly suppresses the progression of protracted EAE, with the median cumulative disease score being reduced from 22 to 14 points, compared to the placebo group; prevents the production of circulating autoantibodies; down‐regulates the synthesis of Th1 cytokines; and induces the production of brain‐derived neurotrophic factor in the central nervous system. Thus, the proposed formulation ameliorates EAE, providing for a less severe first attack and rapid recovery from exacerbation, and offers a promising therapeutic modality in MS treatment.—Belogurov, A. A., Jr., Stepanov, A. V., Smirnov, I. V., Melamed, D., Bacon, A., Mamedov, A. E., Boitsov, V. M., Sashchenko, L. P., Ponomarenko, N. A., Sharanova, S. N., Boyko, A. N., Dubina, M. V., Friboulet, A., Genkin, D. D., Gabibov, A. G. Liposome‐encapsulated peptides protect against experimental allergic encephalitis. FASEB J. 27, 222–231 (2013). www.fasebj.org

30 August 2008 in Doklady Biochemistry and Biophysics
Verified
Journal Article
Closed access
PDF file
FRF. G. Rutberg
F. G. Rutberg
MDMichael Dubina
Michael Dubina
VKV. A. Kolikov
V. A. Kolikov
FMFedor Moiseenko
Fedor Moiseenko
EIE. V. Ignat’EVa
E. V. Ignat’EVa
ASA. Yu. Stogov
A. Yu. Stogov

16 July 2002 in Oncogene
Verified
Journal Article
Closed access
MDMichael Dubina
Michael Dubina
NINikolay A Iatckii
Nikolay A Iatckii
DPDimitrii E Popov
Dimitrii E Popov
SVSergei V Vasil'Ev
Sergei V Vasil'Ev
VKVladimir A Krutovskikh
Vladimir A Krutovskikh